Margaret Ekins Smith
CIK: 0002149973
Transaction Breakdown
Open Market Buys (P)0 (0.0%)
High conviction signal
Open Market Sales (S)0 (0.0%)
Position reduction
Option Exercises (M)0 (0.0%)
Derivative conversions
Awards (A)1 (100.0%)
Compensation grants
Other (G, F, J, C, D, …)0 (0.0%)
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Companies & Roles (1)
SPRY
ARS Pharmaceuticals, Inc.
Officer
Discretionary Trading P&L
Holdings
About Smith Margaret Ekins
Smith Margaret Ekins (SEC CIK 0002149973) files insider reports with the SEC as Chief Commercial Officer of ARS Pharmaceuticals, Inc. (SPRY).
Signal8 holds 2 ownership filings by Smith Margaret Ekins (1 Form 3, 1 Form 4), filed between Aug 17, 2026 and Sep 2, 2026. Those filings report 1 transaction, the latest on Sep 1, 2026. Signal8's Form 4 history starts in Sep 2024.
The business address on Smith Margaret Ekins's filings is in SAN DIEGO, CA.
Recent filings by Smith Margaret Ekins
- Sep 1, 2026: Grant or award of SPRY derivative securities (Form 4, code A).
Other insiders filing for ARS Pharmaceuticals, Inc. (SPRY)
- Casale Donn, President and CEO
- RA CAPITAL MANAGEMENT, L.P., Director
- Dadoo Rajeev, Director
- Shah Pratik, Director
- Kelly Michael, Director
- Islam Saqib, Director